Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lipocine Inc.LPCN · Entity 7696 | Chief Medical Officer | November 01, 2022 | November 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lipocine Inc.
Report date November 01, 2022 · Filed November 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.41 · Expires 2032-11-01 | Direct | 125,000 |
Reported balance
After 2022-11-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-11-01 · Grant · Acquired 125,000 · Balance 125,000 F1: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of November 1, 2023, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorated basis over the following two years. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of November 1, 2023, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorated basis over the following two years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2022 Filed Nov 8, 2022 16:57 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.41 Strike: $0.41 | $50,750.00 |
DisclosureSEC source: 0001493152-22-030909 · ownership.xml · derivative · entry 1 Nomikos George · CIK 0001953799 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-11-01 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of November 1, 2023, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorated basis over the following two years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.